Contingent Consideration (Details) - USD ($) |
Oct. 08, 2025 |
Jun. 30, 2026 |
Dec. 31, 2025 |
|---|---|---|---|
| Contingent Consideration | |||
| Fair value of the Acquisition Obligation | $ 6,465,000 | $ 6,364,000 | |
| ABCJ, LLC | |||
| Contingent Consideration | |||
| Maximum milestone payments | $ 95,000,000 | ||
| Milestone payment period | 10 years | ||
| Fair value of the Acquisition Obligation | $ 6,500,000 | $ 6,400,000 | |
| ABCJ, LLC | First dosing of the Seller Lead Candidate in a patient in a United States Phase 3 Clinical Study | |||
| Contingent Consideration | |||
| Milestone payments payable | $ (5,000,000) | ||
| ABCJ, LLC | Primary endpoint in a United States Phase 3 Clinical Study of the Seller Lead Candidate | |||
| Contingent Consideration | |||
| Milestone payments payable | (10,000,000) | ||
| ABCJ, LLC | First submission of a Biologics License Application | |||
| Contingent Consideration | |||
| Milestone payments payable | (20,000,000) | ||
| ABCJ, LLC | First approval by the FDA of a BLA for the Seller Lead Candidate | |||
| Contingent Consideration | |||
| Milestone payments payable | $ (60,000,000) |